Fish Oil Brain Delivery Study

Conditions

Brain Health

Keywords

Alzheimer's disease, Docosahexaenoic acid, brain health, memory, fish oil, cognition, DHA, omega 3 fatty acid, brain

Brief summary

Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure and function of brain cells. DHA fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. It is not known how much dietary fish oil can get into the human brain. Thus, exploring fish oil delivery in human brains is critical for designing appropriate interventions.

Detailed description

* The investigators goal is to study how different people deliver DHA to the brain. * The study will only require two visits six months apart and involve taking DHA during these 6 months. * Participants will receive DHA supplements for the study duration and a compensation for each study visit. * Blood and cerebrospinal fluid levels of DHA will be measured before and after taking DHA. * Brain imaging by MRI will be obtained at baseline and at conclusion of study * This study will help us learn how much of the ingested DHA goes to the brain.

Hussein N. Yassine, Victoria Solomon, Xulei He, Isabella Cordova, Naoko Kono et al. (11 authors)

Alzheimer s & Dementia2021-12-01

10.1002/alz.055680

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial.

Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE, Kono N, Buennagel DP, Hazra N, Kim G, D'Orazio LM, McCleary C, Sagare A, Zlokovic BV, Hodis HN, Mack WJ, Chui HC, Harrington MG, Braskie MN, Schneider LS, Yassine HN.

2020-07-1794 citations

10.1016/j.ebiom.2020.102883

P4‐055: DHA SUPPLEMENTATION AND BRAIN DELIVERY PILOT STUDY: A RANDOMIZED CLINICAL TRIAL

Hussein N. Yassine, Isabella Cordova, Nicholas Choe, Wenrui Xu, Xulei He et al. (14 authors)

Alzheimer s & Dementia2019-07-01

10.1016/j.jalz.2019.06.3715

Interventions

DIETARY_SUPPLEMENTDocosahexaenoic acid

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* ages 55 and above * at risk of Alzheimer's disease such as family history of dementia * women have to be postmenopausal

Exclusion criteria

1. Current smokers (or a recent history of smoking within less than 5 years), 2. Having a history of cardiovascular disease defined by a prior heart attack, coronary bypass or percutaneous luminal angioplasty, kidney failure or blindness. 3. a diagnosis of cancer in the past 6 months, uncontrolled hyper- or hypothyroidism 4. Taking anti-coagulants such as warfarin 5. Anyone consuming n-3 PUFA capsules for the last 3 months. 6. regular exercisers (\>5 X30min of aerobic exercise per week), 7. heavy drinkers (\>30 units of alcohol per week). One unit of alcohol is about equal to: half a pint of ordinary strength beer, lager or cider (3-4% alcohol by volume); or. a small pub measure (25 ml) of spirits (40% alcohol by volume); or. a standard pub measure (50 ml) of fortified wine such as sherry or port (20% alcohol by volume) 8. If participants have scores that lie 2 SD outside the means of the neuropsychiatry tests administered, they will have mild cognitive impairment. Participant's with mild cognitive impairment are excluded from this study.

Design outcomes

Primary

Measure	Time frame
changes in DHA levels in the CSF following dietary DHA supplementation	6 months

Secondary

Measure	Time frame	Description
Brain MRI	6 months and 1 year	Structural and functional connectivity

Countries

United States

Outcome results

None listed